Fig. 2 (abstract P166).From: 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part OneH3.3K27M peptide induces specific CTL clones from HLA-A2+ donor PBMC. A, B. Patient-derived PBMCs from HLA-A2+H3.3K27M+ tumor patient and healthy donor PBMCs were stimulated with H3.3WT, H3.3K27M peptide, flu peptide, or without peptide (indicated in the X-axis), and co-cultured with T2 cells pulsed with H3.3WT, H3.3K27M, flu peptide, or without peptide. Figure represents numbers of IFN-γ spots generated in each stimulation condition. Counts shown are normalized to no peptide stimulation control. n=3 in each group. *pBack to article page